Dengue Clinical Trials | A Drug Pipeline Analysis Report 2023 | Key companies- Takeda, Merck Sharp & Dohme, AbViro LLC, and others

United States, Nevada, Las Vegas, DelveInsight’s ‘Dengue Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Dengue therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dengue pipeline domain.

Key Takeaways from the Dengue Pipeline Report

• Over 10+ Dengue pipeline therapies are in various stages of development, and their anticipated acceptance in the Dengue market would significantly increase market revenue. 
• Leading Dengue companies developing novel drug candidates to improve the Dengue treatment landscape include Takeda, Merck Sharp & Dohme, AbViro LLC, and others.
• Promising Dengue pipeline therapies in various stages of development include TAK003, V180, AV1, and others.

Dengue Overview

Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Dengue fever is a common mosquito-borne illness in many tropical and subtropical countries. Classic dengue fever, or “break bone fever,” is characterized by acute onset of high fever 3–14 days after the bite of an infected mosquito. Some patients with dengue fever go on to develop dengue hemorrhagic fever (DHF), a severe and sometimes fatal form of the disease. Millions of cases of dengue infection occur worldwide each year. Dengue fever is most common in Southeast Asia, the western Pacific islands, Latin America and Africa. Severe dengue fever happens when blood vessels become damaged and leaky. And the number of clot-forming cells (platelets) in bloodstream drops. This can lead to shock, internal bleeding, organ failure and even death.

Dengue Pipeline Analysis: Drug Profile

AV1: AbViro LLC

AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently Av1 is being studied in phase I in adult healthy individuals.

Discover more about the emerging Dengue drugs @ Dengue Treatment Drugs

Dengue Key Companies

• Takeda
• Merck Sharp & Dohme
• AbViro LLC

Dengue Pipeline Therapies

• TAK003
• V180
• AV1

Dengue Pipeline Therapeutics Assessment

• By development stage
• By product type
• By route of administration
• By molecule type
• By MOA type

Scope of the Dengue Pipeline Report 

• Coverage: Global 
• Key Dengue Companies: Takeda, Merck Sharp & Dohme, AbViro LLC, and others
• Key Dengue Pipeline Therapies: TAK003, V180, AV1, and others

Find out more about the Dengue treatment options in development @ Dengue Clinical Trials

Table of Contents

1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase  II)
7. Early Stage Products (Phase  I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight

Leading Reports by DelveInsight:

• Asthma Diagnostic Devices Market
• Chronic Obstructive Pulmonary Disease Treatment Devices Market
• Airway Management Devices Market
• Cough Assist Devices Market
• Pulse Oximeters Market
• Hemodialysis Catheter Devices Market
• Chronic Spontaneous Urticaria Market
• Gender Dysphoria Market
• Germany Healthcare Outlook
• Biopsy Devices Pipeline Insight
• Bacterial Conjunctivitis Market
• Infliximab Biosimilar Insight
• Eosinophilic Asthma Market
• Cushing Syndrome Market
• Functional Dyspepsia Market
• Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Contact Us

Kritika Rehani

info@delveinsight.com 

+1(919)321-6187